{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.3","upperLimit":"53.5","value":"44.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"}],"units":"Participants"}],"description":"DCR was defined as the percentage of participants who achieved stable disease (SD) or better (MR, PR, VGPR, CR, sCR) for a minimum of 12 weeks. Stable disease (SD): Not recommended for use as an indicator of response; stability of disease was best described by providing the time to progression (TTP) estimates. MR: \\>= 25% but \\< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%. PR: \\>=50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \\>= 90% or to \\< 200 mg per 24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \\< 100 mg per 24 hours; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\<= 5% plasma cells in bone marrow; or sCR: CR as defined+Normal FLC ratio+Absence of clonal cells by immunohistochemistry).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who previously had received more than 3 anti-MM regimens and had penta-exposed, triple class-refractory MM (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an IMiD, a PI, and the anti-CD38 mAb daratumumab) received, selinexor 80 mg PO plus low-dose dexamethasone 20 mg Sd twice-weekly on Days 1 and 3 until disease progression, death, or unacceptable toxicity (maximum duration of approximately 17 months).","id":"OG000","title":"Part 2"}],"paramType":"NUMBER","populationDescription":"mITT population consisted of Part 2 participants with penta-refractory MM who met all eligibility criteria and received at least one dose of study treatment. Data was not planned to be collected and analyzed for Part 1.","reportingStatus":"POSTED","timeFrame":"Every 12 weeks until progressive disease or death due to any cause, up to 17 months","title":"Part 2: Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}